Featured Research

from universities, journals, and other organizations

First Report Of Cancer Drug Gleevec As New Target Therapy For Pulmonary Hypertension

Date:
September 30, 2005
Source:
University of Giessen Lung Center (UGLC)
Summary:
Today, German scientists of the University of Giessen Lung Center (UGLC) published a case study in the Sept. 29 issue of the New England Journal of Medicine (NEJM). The study reveals that the cancer drug Gleevec (Imatinib) may represent a promising new targeted therapy for patients suffering from pulmonary hypertension.

Gleevec (Imatinib) is a representative of the newest generation ofcancer drugs. The substance conveys its potent anti-proliferativeeffect by selectively supressing the tyrosine kinase pathway. TheGiessen lung researchers now issue a first report of this substance asa new target therapy for pulmonary hypertension. "In cancer, tissueproliferation is uncontrolled and leads to the spreading of the tumor,"primary investigator Prof. Friedrich Grimminger of the University ofGiessen Lung Center explained. "In pulmonary hypertension, also,uncontrolled growth of the vascular wall is the underlying mechanism ofthe disease." Pulmonary hypertension is a chronic and life-shorteningvascular disease characterized by high pressure in the lung bloodvessels. The relatively common condition can occur for many reasonssuch as heart disease and various acute and chronic lung ailments. As aresult, the pulmonary arteries thicken and stiffen, causing high bloodpressure and right heart hypertrophy.

Related Articles


In a translational research approach, taking their research "frombench to bedside", Dr. Ralph Schermuly of the same German center onlyrecently described the successful use of Gleevec (Imatinib) in two wellestablished experimental models of progressive pulmonary arterialhypertension. His group found, that the treatment resulted in virtuallycomplete reversal of lung vascular remodeling, pulmonary hypertensionand right heart hypertrophy. The common findings suggest, thatGleevec's uses might expand even further. Co-researcher Dr. ArdeschirGhofrani is convinced, that the results of their studies may open acompletely new therapeutic field of targeted treatment for chronicproliferative diseases such as atherosclerosis, COPD, lung emphysema orlung fibrosis.

Larger clinical trials in a controlled design to test Gleevec's safetyand effectiveness are currently in preparation under the scientificlead of the Giessen lung researchers, who also signed largelyresponsible for the recent appproval of RevatioTM (Sildenafil) for the treatment of pulmonary hypertension in the US.

The UGLC constitutes an interdisciplinary scientific networkincorporating 20 research groups with more than 120 basic scientistsand clinicians, focusing on pulmonary research and treatment of lungdiseases at the University Hospital Giessen, Germany.


Story Source:

The above story is based on materials provided by University of Giessen Lung Center (UGLC). Note: Materials may be edited for content and length.


Cite This Page:

University of Giessen Lung Center (UGLC). "First Report Of Cancer Drug Gleevec As New Target Therapy For Pulmonary Hypertension." ScienceDaily. ScienceDaily, 30 September 2005. <www.sciencedaily.com/releases/2005/09/050930082009.htm>.
University of Giessen Lung Center (UGLC). (2005, September 30). First Report Of Cancer Drug Gleevec As New Target Therapy For Pulmonary Hypertension. ScienceDaily. Retrieved December 19, 2014 from www.sciencedaily.com/releases/2005/09/050930082009.htm
University of Giessen Lung Center (UGLC). "First Report Of Cancer Drug Gleevec As New Target Therapy For Pulmonary Hypertension." ScienceDaily. www.sciencedaily.com/releases/2005/09/050930082009.htm (accessed December 19, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, December 19, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Kids Die While Under Protective Services

Kids Die While Under Protective Services

AP (Dec. 18, 2014) As part of a six-month investigation of child maltreatment deaths, the AP found that hundreds of deaths from horrific abuse and neglect could have been prevented. AP's Haven Daley reports. (Dec. 18) Video provided by AP
Powered by NewsLook.com
Dads-To-Be Also Experience Hormone Changes During Pregnancy

Dads-To-Be Also Experience Hormone Changes During Pregnancy

Newsy (Dec. 18, 2014) A study from University of Michigan researchers found that expectant fathers see a decrease in testosterone as the baby's birth draws near. Video provided by Newsy
Powered by NewsLook.com
Prenatal Exposure To Pollution Might Increase Autism Risk

Prenatal Exposure To Pollution Might Increase Autism Risk

Newsy (Dec. 18, 2014) Harvard researchers found children whose mothers were exposed to high pollution levels in the third trimester were twice as likely to develop autism. Video provided by Newsy
Powered by NewsLook.com
UN: Up to One Million Facing Hunger in Ebola-Hit Countries

UN: Up to One Million Facing Hunger in Ebola-Hit Countries

AFP (Dec. 17, 2014) Border closures, quarantines and crop losses in West African nations battling the Ebola virus could lead to as many as one million people going hungry, UN food agencies said on Wednesday. Duration: 00:52 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins